Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases [Phase 1]
Phase 1 open-label trial investigating [11C]Osimertinib in EGFR-mutant NSCLC with brain metastases; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Lazertinib 160mg in EGFR T790M NSCLC [Phase 2]
Phase 2 clinical trial update for lazertinib 160mg in EGFR T790M non-small cell lung cancer (Stage IV).
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors [Phase 2]
Phase 2 trial evaluating brigatinib after treatment with next-generation ALK inhibitors in non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC [Phase 2]
Phase 2 trial evaluating SBRT and oncolytic virus therapy prior to pembrolizumab in metastatic non-small cell lung cancer and metastatic tri…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC [Phase 1, Phase 2]
Trial update for HS-10296 in non-small cell lung cancer across Phase 1 and Phase 2 evaluating safety, PK, and efficacy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-01-20FDA Approved: LUMAKRAS — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for LUMAKRAS (sotorasib) from Amgen, signaling a regulatory update to the drug's labeling/indication…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients [Phase 3]
Phase 3 trial evaluating HS-10296 as first-line treatment for non-small cell lung cancer. Status and results are not provided in the snippet…
-
EMA approval · 2023-01-19EMA Authorised: Pemetrexed Baxter (pemetrexed disodium heptahydrate) — Baxter Holding B.V.
The EMA authorised Pemetrexed Baxter (pemetrexed disodium heptahydrate) for non-small cell lung carcinoma and mesothelioma.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 [Phase 2]
Phase 2 platform trial update comparing novel regimens against standard of care in non-small cell lung cancer; trial completed with results …
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients [Phase 3]
Phase 3 trial evaluating Exparel and Marcaine for pain management in thoracoscopic lobectomy; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） [Phase 2]
Phase 2 clinical trial update for Utidelone Injection in patients with advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) [Phase 2]
Phase 2 trial results for talazoparib plus avelumab in STK11-mutant stage IV non-small cell lung cancer (LUNG-MAP trial) have been completed…
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 trial investigating serplulimab combined with an anti-VEGF antibody in advanced lung adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC [Phase 2]
Phase 2 trial investigating furmonertinib combined with anlotinib as first-line therapy for EGFR mutation-positive non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Avelumab in First-line NSCLC (JAVELIN Lung 100) [Phase 3]
A Phase 3 trial evaluating first-line avelumab in non-small cell lung cancer has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC [Phase 2]
Phase 2 trial investigating optimal sequencing of pembrolizumab and platinum-based chemotherapy as first-line treatment for non-small cell l…
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI [Phase 3]
Phase 3 trial evaluating toripalimab plus pemetrexed and platinum in advanced non-small cell lung cancer previously treated with EGFR-TKI.
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy [Phase 2]
Phase 2 trial investigating almonertinib in non-small cell lung cancer patients with abnormal liver function after EGFR-TKI treatment or as …
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Evaluation of GLR2007 for Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating GLR2007 for advanced solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment [Phase 2, Phase 3]
Phase II/III study evaluating Tumor Treating Fields (EFE-P100) with docetaxel for stage IV non-small cell lung cancer after progression on p…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Milciclib in Combination With Gemcitabine in Advanced NSCLC [Phase 2]
Phase 2 trial update for milciclib in combination with gemcitabine in advanced non-small cell lung cancer.
-
FDA approval · 2022-12-14FDA Approved: PEMFEXY — Supplemental Application (Eagle Pharmaceuticals, Inc.)
FDA approved a supplemental application for PEMFEXY (pemetrexed) from Eagle Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial [Phase 3]
A phase 3 single-center trial investigating first-line treatment for advanced non-squamous non-small-cell lung cancer without driver mutatio…
-
FDA approval · 2022-12-13FDA Approved: PEMETREXED — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved the original application for pemetrexed disodium from Meitheal Pharmaceuticals Inc., a generic version of the cancer drug pemet…